Markolines Pavem (MARKOLINES)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Lowly levered balance sheet with debt/equity at 0.33
• ROCE of 18.88% and Piotroski F-Score of 7/9 indicate reasonable capital efficiency and financial health
• Promoter holding of 55% keeps management interest aligned with minority shareholders
• Moderate P/E of 13.14 and PEG of 1.18 leave some room if the 14.63% profit growth is sustainable

Concerns

• Topline is stagnant: sales growth only 0.50%; construction demand and order flow may be weak
• ROE of 9.38% is mediocre and below the level I’d demand from a quality compounder
• Civil construction is a low-moat, competitive contract business with limited pricing power
• At ₹150.05 against book value ₹72.82, P/B of 2.06 offers little margin of safety

AI Analysis

I’m drawn to simple businesses, and laying roads and pavements is understandable. But understanding alone is not enough; the business must have a durable advantage. Markolines operates in civil construction, a field where contracts often go to the lowest bidder, entry barriers are low, and pricing power is scarce. That alone stops me from calling it a wonderful business. The financials reinforce caution. Sales growth is just 0.50%—essentially flat. A compounder needs growing revenue; Markolines doesn’t have it. Profit grew 14.63%, which sounds nice, but with stagnant sales I have to ask whether this comes from one-time gains, margin improvements, or unsustainable cost cuts. Latest quarter sales of ₹80 Cr and net profit of ₹7 Cr give a snapshot, but I’d want to see such margins over multiple cycles. On the positive side, debt/equity is 0.33, and Piotroski F-Score of 7/9 suggests decent financial health. ROCE of 18.88% is respectable, though ROE of 9.38% is below what I expect from a great business. Valuation is moderate: P/E 13.14, PEG 1.18, dividend yield 0.92%. Book value is ₹72.82; at ₹150.05 I’m paying more than two times book, so there is little Graham-style margin of safety. The 52-week range of ₹131.65–₹191.75 tells me this can be a volatile, cyclical share. With a market cap of just ₹359 Cr, liquidity and external shocks matter. Promoter holding of 55% is reassuring, but in a cyclical, low-moat industry, alignment alone doesn’t protect me. I also see FairStock Score is unavailable due to insufficient data, reminding me to demand more information. I would need order book visibility, cash flow trends, and a clear margin of safety. At this price, Markolines looks like an average business at a fair price. I’ll pass and wait for better odds.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer